Unknown

Dataset Information

0

Cutoff value of IC50 for drug sensitivity in patient-derived tumor organoids in colorectal cancer.

ABSTRACT: Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC50) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy. After follow-up and comparison of the PDTO drug test and final clinical outcome results, the optimal IC50 cutoff value for PDTO drug sensitivity was 43.26 μmol/L. This PDTO drug test-defined cutoff value could predict patient response with 75.36% sensitivity, 74.68% specificity, and 75% accuracy. Moreover, this value distinguished groups of patients with significant differences in survival benefit. Our study is the first to define the IC50 cutoff value for the PDTO drug test to effectively distinguish CRC patients with chemosensitivity or nonsensitivity and predict survival benefits.

SUBMITTER: Tang Y 

PROVIDER: S-EPMC10329174 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Cutoff value of IC<sub>50</sub> for drug sensitivity in patient-derived tumor organoids in colorectal cancer.

Tang Yuting Y   Wang Ting T   Hu Yaowen Y   Ji Hongli H   Yan Botao B   Hu Xiarong X   Zeng Yunli Y   Hao Yifan Y   Xue Weisong W   Chen Zexin Z   Lan Jianqiang J   Wang Yanan Y   Deng Haijun H   Deng Chuxia C   Wu Xiufeng X   Yan Jun J  

iScience 20230613 7

Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC<sub>50</sub>) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy. After follow-up and comparison of the PDTO drug test and final clinical outcome results,  ...[more]

Similar Datasets

Unknown "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
| S-EPMC9817273 | biostudies-literature
Unknown When Does the IC<sub>50</sub> Accurately Assess the Blocking Potency of a Drug?
| S-EPMC7357848 | biostudies-literature
Proteomics Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction
2025-02-03 | PXD038149 | Pride
Unknown Gene-signature-derived IC<sub>50</sub>s/EC<sub>50</sub>s reflect the potency of causative upstream targets and downstream phenotypes.
| S-EPMC7295968 | biostudies-literature
Unknown Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.
| S-EPMC5127645 | biostudies-literature
Unknown Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids.
| S-EPMC8330527 | biostudies-literature
Unknown Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC<sub>50</sub> Values in Aging and Alzheimer's Disease, Using the Physiologically Based LeiCNS-PK3.0 Model.
| S-EPMC9246802 | biostudies-literature
Unknown Systematic review: predictive value of organoids in colorectal cancer.
| S-EPMC10593775 | biostudies-literature
Unknown Evaluation of IC<sub>50</sub> levels immediately after treatment with anticancer reagents using a real-time cell monitoring device.
| S-EPMC6755379 | biostudies-literature
Unknown Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
| S-EPMC8366292 | biostudies-literature